Skip to main content

BRIEF RESEARCH REPORT article

Front. Neurol.
Sec. Movement Disorders
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1501206

Montreal Cognitive Assessment as a cognitive outcome measure in progressive supranuclear palsy

Provisionally accepted
Vanessa Ibrahim Vanessa Ibrahim 1*Catherine Isroff Catherine Isroff 1Christopher D Stephen Christopher D Stephen 2Jay Iyer Jay Iyer 3Marian L Dale Marian L Dale 4Douglas A Gunzler Douglas A Gunzler 5Ece Bayram Ece Bayram 6Tao Xie Tao Xie 7Alexander Pantelyat Alexander Pantelyat 8Leila Montaser Kouhsari Leila Montaser Kouhsari 9Indira Garcia-Cordero Indira Garcia-Cordero 10Maria Carmela Tartaglia Maria Carmela Tartaglia 10Anthony Lang Anthony Lang 11,12Matthew Swan Matthew Swan 13Adam L Boxer Adam L Boxer 14Lawrence Golbe Lawrence Golbe 15Anne-Marie Wills Anne-Marie Wills 1*
  • 1 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States
  • 2 Massachusetts General Hospital, Harvard Medical School, Boston, United States
  • 3 Department of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, Massachusetts, United States
  • 4 Department of Neurology, Oregon Health and Science University, Portland, Oregon, United States
  • 5 Population Health and Equity Research Institute Center for Health Care Research & Policy, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, United States
  • 6 Movement Disorders Center, Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • 7 Movement Disorders Program, Department of Neurology, University of Chicago Medicine, Chicago, Illinois, United States
  • 8 Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States
  • 9 Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • 10 Tanz Centre for Research on Neurodegenerative Diseases, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 11 Krembil Brain Institute, University Health Network (UHN), Toronto, Ontario, Canada
  • 12 Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Krembil Neuroscience Centre (KNC), Toronto Western Hospital, Toronto, Ontario, Canada
  • 13 Department of Neurology, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • 14 Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, United States
  • 15 Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States

The final, formatted version of the article will be published soon.

    BACKGROUND The Montreal Cognitive assessment (MoCA) is a well-validated global cognitive screening instrument. Its validity in progressive supranuclear palsy (PSP) has not been assessed. OBJECTIVES To evaluate the MoCA as an outcome measure in PSP clinical trials. METHODS Cognitive data from 162 participants in the placebo arm of the Biogen PASSPORT study (NCT03068468) were analyzed using linear mixed-effects modeling (LMM) and repeated measures correlation.There was a significant decline in the MoCA score over time of -1.4 (95% CI -0.84 to -1.97) points over a 48-week period (p < 0.0001). Small but significant changes (p < 0.01) were observed in all MoCA domains except abstraction. The MoCA correlated weakly with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) over time (rrm = 0.1, p = 0.02) but exhibited a stronger correlation with the PSP Rating Scale (PSPRS) (rrm = -0.25, p < 0.0001).The MoCA appears to have limited sensitivity in capturing cognitive decline in PSP.

    Keywords: MoCA = Montreal Cognitive Assessment, Psp, Outcome measure, Movement Disorders, Progressive supranucelar palsy

    Received: 24 Sep 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Ibrahim, Isroff, Stephen, Iyer, Dale, Gunzler, Bayram, Xie, Pantelyat, Montaser Kouhsari, Garcia-Cordero, Tartaglia, Lang, Swan, Boxer, Golbe and Wills. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Vanessa Ibrahim, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Anne-Marie Wills, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.